Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy

Authors

  • Carolyn Luscombe,

    1. Macfarlane Burnet Centre for Medical Research and Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Fairfield, Victoria
    Search for more papers by this author
  • John Pedersen,

    1. Melbourne Pathology, Fitzroy, Victoria, Australia
    Search for more papers by this author
  • Scott Bowden,

    1. Macfarlane Burnet Centre for Medical Research and Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Fairfield, Victoria
    Search for more papers by this author
  • Stephen Locarnini

    Corresponding author
    1. Macfarlane Burnet Centre for Medical Research and Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Fairfield, Victoria
      Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Yarra Bend Road, Fairfield, Victoria, Australia, 3078
    Search for more papers by this author

Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Yarra Bend Road, Fairfield, Victoria, Australia, 3078

Abstract

Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the guanosine analogue, ganciclovir, and the effect on serum and intrahepatic expression of DHBV DNA and viral proteins was examined. After 21 days of ganciclovir treatment, a substantial reduction in viraemia occurred; in contrast, the level of circulating DHBV surface antigen was unchanged. Ganciclovir therapy also substantially reduced the level of DHBV DNA replicative intermediates and the expression of viral core and surface antigen in hepatocytes. However, despite the antiviral treatment some liver cells, including the bile duct epithelial cells and putative oval cells, maintained their intense staining for the viral proteins. Furthermore, DHBV-infected cells in extrahepatic sites such as the pancreas, kidney and spleen were also unaffected by ganciclovir treatment. These results suggest that monotherapy with nucleoside analogues is unlikely to eliminate chronic hepadnaviral infection, and antiviral programs should be designed to target all cell populations infected by the virus.

Ancillary